Hiroki Ishihara, MD, PhD is an expert in Oncology at Kawaguchi Junior College (Japan). As of October 2026, ScienceLeadR ranks Hiroki Ishihara in the top 1% of experts worldwide for Kidney Neoplasms, Urologic Neoplasms and Carcinoma. Hiroki Ishihara has authored 162 publications, the most recent in 2026. SLR score: 519 (community average: 125). How the SLR is computed.

LeadR Profile

Hiroki Ishihara, MD, PhD Kawaguchi Junior College Japan
519 ScienceLeadR Reputation 519
Network Map

Oncology

Subspecialties: Urology - Nephrology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 2015 - 2026

Source: PubMed

Tokyo Women's Medical University

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 162

Citations

Citations: 1 535 1st author: 81 Last author: 4 Unique author: 2


Best Journals

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Factors Associated With Trifecta and Pentafecta Achievement in Robot-Assisted Laparoscopic Partial Nephrectomy for Highly Complex Renal Tumors.
PMID 42865126 — achievement, minimally invasive surgical procedures, neoplasms, nephrectomy, carcinoma, renal cell
Int J Urol20260
Prognostic impact of lenvatinib dose intensity in previously untreated patients with advanced renal cell carcinoma receiving lenvatinib plus pembrolizumab.
PMID 42847603 — cells, neoplasms, carcinoma, renal cell, immunotherapy, drug-related side effects and adverse reactions, immune checkpoint inhibitors, kidney neoplasms, therapeutics
Jpn J Clin Oncol20260
Effectiveness and Safety of Enfortumab Vedotin Plus Pembrolizumab for Patients Aged 80 Years and Older With Metastatic Urothelial Carcinoma: A Multicenter Retrospective Study.
PMID 42527056 — safety, retrospective studies, aged, therapeutics
Anticancer Res20260
Future direction of systemic therapy for advanced renal cell carcinoma: lessons from final and extended follow-up data from the CheckMate 9ER trial.
PMID 42293852 — cells, carcinoma, renal cell, nivolumab, therapeutics
Transl Androl Urol20260
Real-World Outcomes of Adjuvant Pembrolizumab for Renal Cell Carcinoma: The Potential Role of PD-L1 as a Prognostic Biomarker.
PMID 42240722 — cells, safety, neoplasms, carcinoma, renal cell, biomarkers, therapeutics
Target Oncol20260

LeadR Networks

Main global connection map